Background: Warfarin has provided protection against cardioembolic stroke in the setting of
nonvalvular atrial fibrillation (NVAF) for the past 60 years. Dabigatran, the first oral direct …

Background: Atrial fibrillation (AF) causes a significant health and economic burden to the
Dutch society. Dabigatran was proven to have at least similar efficacy and a similar or better …

Introduction: Dabigatran and warfarin have been shown to be non-inferior for stroke
prevention in atrial fibrillation (AF). We aimed to assess the cost perspectives of each payer …

Because atrial fibrillation is associated with advanced age and obesity, its prevalence is
increasing worldwide. 1 New treatments such as ablation and left atrial occlusion may …

Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …

The authors of the present work extracted data from trials of anticoagulant therapy in order to
estimate the cost-effectiveness of dabigatran compared with warfarin for the prevention of …

Objectives Dabigatran has shown to be effective in preventing embolic events in chronic
atrial fibrillation patients, but it's cost-utility has not been assessed in Argentina. Therefore …

Objectives The goal of this study was to provide with “real world” estimations of the cost-
effectiveness of two direct oral anticoagulants (DOA), dabigatran, and rivaroxaban, versus …